Skip to main content
Top
Published in: Internal and Emergency Medicine 4/2014

01-06-2014 | IM - REVIEW

Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?

Authors: Giovanni Cammarota, Gianluca Ianiro, Stefano Bibbò, Antonio Gasbarrini

Published in: Internal and Emergency Medicine | Issue 4/2014

Login to get access

Abstract

Gut microbiota is known to have a relevant role in our health, and is also related to both gastrointestinal and extradigestive diseases. Therefore, restoring the alteration of gut microbiota represents an outstanding clinical target for the treatment of gut microbiota-related diseases. The modulation of gut microbiota is perhaps an ancestral, innate concept for human beings. At this time, the restoration of gut microbiota impairment is a well-established concept in mainstream medicine, and several therapeutic approaches have been developed in this regard. Antibiotics, prebiotics and probiotics are the best known and commercially available options to overcome gastrointestinal dysbiosis. Fecal microbiota transplantation is an old procedure that has recently become popular again. It has shown a clear effectiveness in the treatment of C. difficile infection, and now represents a cutting-edge option for the restoration of gut microbiota. Nevertheless, such weapons should be used with caution. Antibiotics can indeed harm and alter gut microbiota composition. Probiotics, instead, are not at all the same thing, and thinking in terms of different strains is probably the only way to improve clinical outcomes. Moreover, fecal microbiota transplantation has shown promising results, but stronger proofs are needed. Considerable efforts are needed to increase our knowledge in the field of gut microbiota, especially with regard to the future use in its modulation for therapeutic purposes.
Literature
1.
go back to reference Bäckhed F, Ley RE, Sonnenburg JL et al (2005) Host-bacterial mutualism in the human intestine. Science 307:1915–1920PubMedCrossRef Bäckhed F, Ley RE, Sonnenburg JL et al (2005) Host-bacterial mutualism in the human intestine. Science 307:1915–1920PubMedCrossRef
3.
go back to reference Zoetendal EG, Rajilic-Stojanovic M, de Vos WM (2008) High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57:1605–1615PubMedCrossRef Zoetendal EG, Rajilic-Stojanovic M, de Vos WM (2008) High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57:1605–1615PubMedCrossRef
4.
go back to reference Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, MetaHIT Consortium, Bork P, Ehrlich SD, Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59–65PubMedCentralPubMedCrossRef Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, MetaHIT Consortium, Bork P, Ehrlich SD, Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59–65PubMedCentralPubMedCrossRef
5.
go back to reference Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489(7415):220–230PubMedCentralPubMedCrossRef Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489(7415):220–230PubMedCentralPubMedCrossRef
8.
go back to reference David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ (2013) Diet rapidly and reproducibly alters the human gut microbiome. Nature. doi: 10.1038/nature12820 (Epub ahead of print PMID: 24336217) David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ (2013) Diet rapidly and reproducibly alters the human gut microbiome. Nature. doi: 10.​1038/​nature12820 (Epub ahead of print PMID: 24336217)
10.
go back to reference Spor A, Koren O, Ley RE (2011) Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 9:279–290PubMedCrossRef Spor A, Koren O, Ley RE (2011) Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 9:279–290PubMedCrossRef
11.
13.
go back to reference Manichanh C, Borruel N, Casellas F et al (2012) The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9:599–608PubMedCrossRef Manichanh C, Borruel N, Casellas F et al (2012) The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9:599–608PubMedCrossRef
14.
go back to reference Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG, Rome Foundation Committee (2013) Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 159–176. doi:10.1136/gutjnl-2012-302167 (Epub 2012 Jun 22. PMID: 22730468) Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG, Rome Foundation Committee (2013) Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 159–176. doi:10.​1136/​gutjnl-2012-302167 (Epub 2012 Jun 22. PMID: 22730468)
17.
go back to reference Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K (2013) Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 19(4):338–348. doi:10.1111/1469-0691.12140 (Epub 2013 Mar 2. Review. PMID: 23452163)PubMedCrossRef Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K (2013) Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 19(4):338–348. doi:10.​1111/​1469-0691.​12140 (Epub 2013 Mar 2. Review. PMID: 23452163)PubMedCrossRef
24.
go back to reference Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577–594PubMedCrossRef Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577–594PubMedCrossRef
25.
go back to reference Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y (2012) Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24(6):521–530, e248. doi: 10.1111/j.1365-2982.2012.01891.x (Epub 2012 Feb 20) Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y (2012) Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24(6):521–530, e248. doi: 10.​1111/​j.​1365-2982.​2012.​01891.​x (Epub 2012 Feb 20)
26.
go back to reference Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464):541–546. doi:10.1038/nature12506 PubMedCrossRef Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464):541–546. doi:10.​1038/​nature12506 PubMedCrossRef
27.
go back to reference Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI (2009) A core gut microbiome in obese and lean twins. Nature 457(7228):480–484. doi:10.1038/nature07540 PubMedCentralPubMedCrossRef Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI (2009) A core gut microbiome in obese and lean twins. Nature 457(7228):480–484. doi:10.​1038/​nature07540 PubMedCentralPubMedCrossRef
28.
go back to reference Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC (2013) Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy. doi:10.1111/cea.12253 (Epub ahead of print PMID: 24330256) Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC (2013) Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy. doi:10.​1111/​cea.​12253 (Epub ahead of print PMID: 24330256)
31.
go back to reference Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y, Study Group participants (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62(1):34–42. doi:10.1136/gutjnl-2012-302254 (Epub 2012 May 12. PMID: 22580412)PubMedCrossRef Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y, Study Group participants (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62(1):34–42. doi:10.​1136/​gutjnl-2012-302254 (Epub 2012 May 12. PMID: 22580412)PubMedCrossRef
32.
go back to reference Jernberg C, Löfmark S, Edlund C, Jansson JK (2010) Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156:3216–3223PubMedCrossRef Jernberg C, Löfmark S, Edlund C, Jansson JK (2010) Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156:3216–3223PubMedCrossRef
33.
go back to reference Hopkins MJ, Macfarlane GT (2003) Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 69:1920–1927PubMedCentralPubMedCrossRef Hopkins MJ, Macfarlane GT (2003) Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 69:1920–1927PubMedCentralPubMedCrossRef
34.
go back to reference Stiemsma LT, Turvey SE, Finlay BB (2013) An antibiotic-altered microbiota provides fuel for the enteric foe. Cell Res. doi:10.1038/cr.2013.142 (Epub ahead of print) Stiemsma LT, Turvey SE, Finlay BB (2013) An antibiotic-altered microbiota provides fuel for the enteric foe. Cell Res. doi:10.​1038/​cr.​2013.​142 (Epub ahead of print)
36.
go back to reference Murphy R1, Stewart AW2, Braithwaite I3, Beasley R3, Hancox RJ4, Mitchell EA5; the ISAAC Phase Three Study Group (2013) Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. Int J Obes (Lond). doi:10.1038/ijo.2013.218 (Epub ahead of print) Murphy R1, Stewart AW2, Braithwaite I3, Beasley R3, Hancox RJ4, Mitchell EA5; the ISAAC Phase Three Study Group (2013) Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. Int J Obes (Lond). doi:10.​1038/​ijo.​2013.​218 (Epub ahead of print)
37.
go back to reference Willing BP, Russell SL, Finlay BB (2011) Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol 9:233–243PubMedCrossRef Willing BP, Russell SL, Finlay BB (2011) Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol 9:233–243PubMedCrossRef
39.
go back to reference Schlundt J (2001) Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO/WHO Schlundt J (2001) Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO/WHO
40.
41.
go back to reference Ng SC et al (2009) Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 15(2):300–310PubMedCrossRef Ng SC et al (2009) Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 15(2):300–310PubMedCrossRef
42.
go back to reference Hickson M (2013) Examining the evidence for the use of probiotics in clinical practice. Nurs Stand 27(29):35–41PubMedCrossRef Hickson M (2013) Examining the evidence for the use of probiotics in clinical practice. Nurs Stand 27(29):35–41PubMedCrossRef
43.
go back to reference Bron PA, van Baarlen P, Kleerebezem M (2012) Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 10:66–78 Bron PA, van Baarlen P, Kleerebezem M (2012) Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 10:66–78
44.
go back to reference Van Baarlen P, Troost F, van der Meer C et al (2011) Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci USA 108(Suppl 1):4562–4569PubMedCentralPubMedCrossRef Van Baarlen P, Troost F, van der Meer C et al (2011) Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci USA 108(Suppl 1):4562–4569PubMedCentralPubMedCrossRef
45.
go back to reference O’Mahony L, McCarthy J, Kelly P et al (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551PubMedCrossRef O’Mahony L, McCarthy J, Kelly P et al (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551PubMedCrossRef
47.
go back to reference Gibson GR, Roberfroid MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125:1401–1412PubMed Gibson GR, Roberfroid MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 125:1401–1412PubMed
49.
go back to reference Roberfroid MB (2007) Prebiotics: the concept revisited. J Nutr 137(3 Suppl 2):830S–837S (PMID 17311983)PubMed Roberfroid MB (2007) Prebiotics: the concept revisited. J Nutr 137(3 Suppl 2):830S–837S (PMID 17311983)PubMed
50.
go back to reference Langlands SJ, Hopkins MJ, Coleman N, Cummings JH (2004) Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 53:1610–1616PubMedCentralPubMedCrossRef Langlands SJ, Hopkins MJ, Coleman N, Cummings JH (2004) Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 53:1610–1616PubMedCentralPubMedCrossRef
51.
go back to reference Duncan SH, Scott KP, Ramsay AG, Harmsen HJ, Welling GW, Stewart CS et al (2003) Effects of alternative dietary substrates on competition between human colonic bacteria in an anaerobic fermentor system. Appl Environ Microbiol 69:1136–1142PubMedCentralPubMedCrossRef Duncan SH, Scott KP, Ramsay AG, Harmsen HJ, Welling GW, Stewart CS et al (2003) Effects of alternative dietary substrates on competition between human colonic bacteria in an anaerobic fermentor system. Appl Environ Microbiol 69:1136–1142PubMedCentralPubMedCrossRef
52.
go back to reference de Vrese M, Marteau PR (2007) Probiotics and prebiotics: effects on diarrhea. J Nutr 137(Suppl. 2):11S–803S de Vrese M, Marteau PR (2007) Probiotics and prebiotics: effects on diarrhea. J Nutr 137(Suppl. 2):11S–803S
53.
go back to reference Zhang F, Luo W, Shi Y et al (2012) Should we standardize the 1700-year old fecal microbiota transplantation? Am J Gastroenterol 107:1755PubMedCrossRef Zhang F, Luo W, Shi Y et al (2012) Should we standardize the 1700-year old fecal microbiota transplantation? Am J Gastroenterol 107:1755PubMedCrossRef
54.
go back to reference Borody TJ, Warren EF, Leis SM et al (2004) Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 38:475–483PubMedCrossRef Borody TJ, Warren EF, Leis SM et al (2004) Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 38:475–483PubMedCrossRef
55.
go back to reference Lewis A (1999) Merde: excursions in scientific, cultural, and socio-historical coprology. Random House, New York, NY Lewis A (1999) Merde: excursions in scientific, cultural, and socio-historical coprology. Random House, New York, NY
56.
go back to reference Eiseman B, Silen W, Bascom GS et al (1958) Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44:854–859PubMed Eiseman B, Silen W, Bascom GS et al (1958) Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44:854–859PubMed
58.
go back to reference Pepin J, Alary ME, Valiquette L et al (2005) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40:1591–1597PubMedCrossRef Pepin J, Alary ME, Valiquette L et al (2005) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40:1591–1597PubMedCrossRef
59.
go back to reference Mattila E, Uusitalo-Seppälä R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, Moilanen V, Salminen K, Seppälä M, Mattila PS, Anttila VJ, Arkkila P (2012) Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142(3):490–496. doi:10.1053/j.gastro.2011.11.037 (Epub 2011 Dec 7. PMID: 2215536)PubMedCrossRef Mattila E, Uusitalo-Seppälä R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, Moilanen V, Salminen K, Seppälä M, Mattila PS, Anttila VJ, Arkkila P (2012) Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142(3):490–496. doi:10.​1053/​j.​gastro.​2011.​11.​037 (Epub 2011 Dec 7. PMID: 2215536)PubMedCrossRef
60.
go back to reference van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368(5):407–415. doi:10.1056/NEJMoa1205037 (Epub 2013 Jan 16. PMID: 23323867)PubMedCrossRef van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368(5):407–415. doi:10.​1056/​NEJMoa1205037 (Epub 2013 Jan 16. PMID: 23323867)PubMedCrossRef
62.
go back to reference Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4):913–916.e7. doi:10.1053/j.gastro.2012.06.031 (PMID: 22728514) Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4):913–916.e7. doi:10.​1053/​j.​gastro.​2012.​06.​031 (PMID: 22728514)
64.
go back to reference Grehan MJ, Borody TJ, Leis SM et al (2010) Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 44:551–561PubMedCrossRef Grehan MJ, Borody TJ, Leis SM et al (2010) Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 44:551–561PubMedCrossRef
65.
go back to reference Tannock G, Munro K, Harmsen H et al (2000) Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 66:2578–2588PubMedCentralPubMedCrossRef Tannock G, Munro K, Harmsen H et al (2000) Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 66:2578–2588PubMedCentralPubMedCrossRef
66.
go back to reference Borody TJ, Khoruts A (2012) Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9:88–96CrossRef Borody TJ, Khoruts A (2012) Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9:88–96CrossRef
67.
go back to reference Bakken JS, Borody T, Brandt LJ et al (2011) Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9:1044–1049PubMedCentralPubMedCrossRef Bakken JS, Borody T, Brandt LJ et al (2011) Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9:1044–1049PubMedCentralPubMedCrossRef
68.
go back to reference Cammarota G, Ianiro G, Gasbarrini A (2014) Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol (Epub ahead of print) Cammarota G, Ianiro G, Gasbarrini A (2014) Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol (Epub ahead of print)
69.
go back to reference Persky S, Brandt LJ (2000) Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly though a colonoscope. Am J Gastroenterol 95:3283–3285PubMed Persky S, Brandt LJ (2000) Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly though a colonoscope. Am J Gastroenterol 95:3283–3285PubMed
70.
go back to reference Brandt LJ, Reddy SS (2011) Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 45:S159–S167PubMedCrossRef Brandt LJ, Reddy SS (2011) Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 45:S159–S167PubMedCrossRef
71.
go back to reference Silverman MS, Davis I, Pillai DR (2010) Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 8:471–473PubMedCrossRef Silverman MS, Davis I, Pillai DR (2010) Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 8:471–473PubMedCrossRef
72.
go back to reference Burns DA, Heap JT, Minton NP (2010) Clostridium difficile spore germination: an update. Res Microbiol 161:730–734PubMedCrossRef Burns DA, Heap JT, Minton NP (2010) Clostridium difficile spore germination: an update. Res Microbiol 161:730–734PubMedCrossRef
73.
go back to reference Damman CJ, Miller SI, Surawicz CM, Zisman TL (2012) The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 107(10):1452–1459. doi:10.1038/ajg.2012.93 PubMedCrossRef Damman CJ, Miller SI, Surawicz CM, Zisman TL (2012) The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 107(10):1452–1459. doi:10.​1038/​ajg.​2012.​93 PubMedCrossRef
74.
go back to reference Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D (2013) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108(10):1620–1630. doi:10.1038/ajg.2013.257 (Epub 2013 Sep 24. PMID: 24060759)PubMedCrossRef Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D (2013) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108(10):1620–1630. doi:10.​1038/​ajg.​2013.​257 (Epub 2013 Sep 24. PMID: 24060759)PubMedCrossRef
75.
go back to reference El-Matary W, Simpson R, Ricketts-Burns N (2012) Fecal microbiota transplantation: are we opening a can of worms? Gastroenterology 143:e19–e20PubMedCrossRef El-Matary W, Simpson R, Ricketts-Burns N (2012) Fecal microbiota transplantation: are we opening a can of worms? Gastroenterology 143:e19–e20PubMedCrossRef
76.
go back to reference Gough E, Shaikh H, Manges AR (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:994–1002PubMedCrossRef Gough E, Shaikh H, Manges AR (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:994–1002PubMedCrossRef
77.
go back to reference Brandt LJ (2013) Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 108(2):177–185. doi:10.1038/ajg.2012.450 (Epub 2013 Jan 15. Review. PMID: 23318479)PubMedCrossRef Brandt LJ (2013) Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 108(2):177–185. doi:10.​1038/​ajg.​2012.​450 (Epub 2013 Jan 15. Review. PMID: 23318479)PubMedCrossRef
80.
go back to reference Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A (2012) Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107:761–767PubMedCrossRef Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A (2012) Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107:761–767PubMedCrossRef
81.
go back to reference Metchnikoff E, Mitchell PCS (1907) The prolongation of life: optimistic studies. William Heinemann, London Metchnikoff E, Mitchell PCS (1907) The prolongation of life: optimistic studies. William Heinemann, London
Metadata
Title
Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?
Authors
Giovanni Cammarota
Gianluca Ianiro
Stefano Bibbò
Antonio Gasbarrini
Publication date
01-06-2014
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 4/2014
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-014-1069-4

Other articles of this Issue 4/2014

Internal and Emergency Medicine 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine